Mechanics Bank Trust Department lifted its position in Amgen Inc. (NASDAQ:AMGN) by 4.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,649 shares of the medical research company’s stock after acquiring an additional 140 shares during the period. Mechanics Bank Trust Department’s holdings in Amgen were worth $628,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in AMGN. Palisade Capital Management LLC NJ purchased a new position in Amgen during the first quarter valued at approximately $456,000. Evanson Asset Management LLC grew its position in Amgen by 4.7% during the first quarter. Evanson Asset Management LLC now owns 1,476 shares of the medical research company’s stock valued at $242,000 after purchasing an additional 66 shares in the last quarter. DnB Asset Management AS grew its position in Amgen by 8.9% during the first quarter. DnB Asset Management AS now owns 78,666 shares of the medical research company’s stock valued at $12,907,000 after purchasing an additional 6,400 shares in the last quarter. Bank of The West grew its position in Amgen by 7.2% during the first quarter. Bank of The West now owns 18,828 shares of the medical research company’s stock valued at $3,089,000 after purchasing an additional 1,258 shares in the last quarter. Finally, Greylin Investment Mangement Inc. grew its position in Amgen by 21.0% during the first quarter. Greylin Investment Mangement Inc. now owns 2,475 shares of the medical research company’s stock valued at $406,000 after purchasing an additional 430 shares in the last quarter. 78.14% of the stock is currently owned by institutional investors and hedge funds.

Shares of Amgen Inc. (NASDAQ AMGN) traded down 1.25% during trading on Friday, reaching $187.07. 2,370,650 shares of the company were exchanged. The stock has a market capitalization of $136.50 billion, a price-to-earnings ratio of 17.04 and a beta of 1.35. The company has a 50 day moving average price of $174.87 and a 200-day moving average price of $169.24. Amgen Inc. has a one year low of $133.64 and a one year high of $191.10.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. During the same quarter in the prior year, the firm posted $2.84 EPS. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. Equities analysts predict that Amgen Inc. will post $12.57 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Thursday, August 17th were issued a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.43%. The ex-dividend date was Tuesday, August 15th. Amgen’s dividend payout ratio is 41.93%.

AMGN has been the topic of a number of research analyst reports. Cann reaffirmed a “buy” rating on shares of Amgen in a research report on Monday, August 28th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $203.00 price objective on shares of Amgen in a research report on Thursday, September 7th. Deutsche Bank AG initiated coverage on shares of Amgen in a research report on Friday, June 23rd. They set a “hold” rating and a $172.00 price objective on the stock. ValuEngine downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, William Blair reaffirmed a “market perform” rating on shares of Amgen in a research report on Monday, June 26th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Amgen presently has an average rating of “Buy” and a consensus price target of $186.14.

ILLEGAL ACTIVITY NOTICE: “Mechanics Bank Trust Department Has $628,000 Stake in Amgen Inc. (AMGN)” was reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/09/15/mechanics-bank-trust-department-has-628000-stake-in-amgen-inc-amgn.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.